Occupational history and genetic N-acetyltransferase polymorphism in urothelial cancer patients of Leverkusen, Germany

Scandinavian Journal of Work, Environment and Health

Volumn 22, Issue 5, 1996, Pages 332-338

  Golka, Klaus ^a   Prior, Verena ^b   Blaszkewicz, Meinolf ^a   Cascorbi, Ingolf ^c   Schöps, Wolfgang ^b   Kierfeld, Gerd ^b   Roots, Ivar ^c   Bolt, Hermann M ^a  

^a LEIBNIZ RESEARCH CENTRE FOR WORKING ENVIRONMENT AND HUMAN FACTORS   (Germany)

^b KLINIKUM LEVERKUSEN   (Germany)

^c HUMBOLDT UNIVERSITY   (Germany)

Author keywords

Acetylation phenotype; Aromatic amines; Bladder cancer

Indexed keywords

ACYLTRANSFERASE; AROMATIC AMINE; BENZIDINE;

ARTICLE; BLADDER CANCER; CANCER RISK; CHEMICAL INDUSTRY; CONTROLLED STUDY; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; GERMANY; HUMAN; INTERVIEW; MAJOR CLINICAL STUDY; MALE; OCCUPATIONAL EXPOSURE; PRIORITY JOURNAL; RISK FACTOR; RUBBER INDUSTRY;

EID: 0029827668     PISSN: 03553140     EISSN: None     Source Type: Journal    
DOI: 10.5271/sjweh.150     Document Type: Article

References (39)

1. Cartwright R, Ahmad RA, Barham-Hall D, Glashan RW, Rogers HJ, Higgins E, et al. Role of N-acelyltransferase phenotypes in bladder carcinogenesis: a pharmacogenetic epidemiological approach to bladder cancer. Lancet 1982;2:842-5.
2. Lower GM Jr, Nilsson T, Nelson CE, Wolf H, Gamsky TE, Bryan GT. N-Acetyltransferase phenotype and risk in urinary bladder cancer: approaches in molecular epidemiology: preliminary results in Sweden and Denmark. Environ Health Perspect 1979;29:71-9.
3. Lower GM Jr, Bryan GT. Etiology and carcinogenesis: natural system approaches to causality and control. In: Javadpour N, editor. Principles and management of urologic cancer. Baltimore (MA): Williams and Wilkins Company, 1979:29-53.
4. Wolf H, Lower GM Jr, Bryan GT. Role of N-acetyltransferase phenotype in human susceptibility to bladder carcinogenic arylamines. Scand J Urol Nephrol 1980;14:161-5.
5. Woodhouse KW, Adams PC, Clothier A, Mucklow JC, Rawlins MC. N-Acetylation phenotype in bladder cancer. Hum Toxicol 1982;1:443-5.
6. Evans DAP, Eze LC, Whibley EJ. The association of the slow acetylator phenotype with bladder cancer. J Med Genet 1983;20:330-3.
7. Miller ME, Cosgriff JM. Acetylator phenotype in human bladder cancer. J Urol 1983;130:65-6.
8. Mommsen S, Barfod NM, Aagaard J. N-Acetyltransferase phenotypes in the urinary bladder carcinogenesis of a low-risk population. Carcinogenesis 1985;6:199-201.
9. Hanssen HP, Agarwal DP, Goedde HW, Bucher H, Huland H, Brachmann W, et al. Association of the N-acetyltransferase polymorphism and environmental factors with bladder carcinogenesis. Eur Urol 1985;11:263-6.
10. Ladero JM, Kwok CK, Jara C, Fernandez L, Silmi AM, Tapia D, et al. Hepatic acetylator phenotype in bladder cancer patients. Ann Clin Res 1985;17:96-9.
11. Hanke J, Krajewska B. Acetylation phenotypes and bladder cancer. J Occup Med 1990;32:917-8.
12. Roots I, Drakoulis N, Brockmöller J. Polymorphic enzymes and cancer risk: concepts, methodology and data review. In: Kalow W, editor. Pharmacogenetics of drug metabolism, New York (NY): Pergamon, 1992:815-41.
13. Cascorbi I, Drakoulis N, Brockmöller J, Maurer A, Mrozikiewicz P, Roots I. Polymorphisms of the human arylamine N- acetyltransferase (NAT2) gene in German bladder cancer patients [abstract]. Naunyn-Schmiedeberg's Arch Pharmacol 1994;suppl 349:R 132.
14. Vineis P. The use of biomarkers in epidemiology: the example of bladder cancer. Toxicol Lett 1992;64/65:463-7.
15. Karakaya AE, Cok L, Sardas S, Gögüs O. Acetyltransferase phenotype of patients with bladder cancer. Hum Toxicol 1986; 5:333-5.
16. Horai Y, Fujita K, Ishizaki T. Genetically determined N- acetylation and oxidation capacities in Japanese patients with non-occupational urinary bladder cancer. Eur J Clin Pharmacol 1989;37:581-7.
17. Hayes RB, Bi W, Rothman N, Broly F, Caporaso N, Feng P, et al. N-Acetylation phenotype and genotype and risk of bladder cancer in benzidine-exposed workers. Carcinogenesis 1993; 14:675-8.
18. Lewalter J, Miksche L. Empfehlungen zur arbeitsmedizinischen Prävention expositions- und dispositionsbedingter Arbeitsstoff-Beanspruchungen. 3l. Jahrestagung der Deutschen Gesellschaft für Arbeitsmedizin. Stuttgart: Gentner Verlag 1991:135-9
19. Caporaso N, Landi MT, Vineis P. Relevance of metabolic polymorphisms to human Carcinogenesis: evaluation of epidemiologic evidence. Pharmacogenetics 1991;1:4-19.
20. Myslak ZW, Bolt HM. Berufliche Exposition gegenüber Azofarbstoffen und Harnblasenkarzinom-Risiko. Zbl Arbeitsmed 1988;38:310-21.
21. Grant DM, Tang BK, Kalow W. A simple test for acetylator phenotype using caffeine. Br J Clin Pharmacol 1984;17:459-64.
22. Prior V. Untersuchungen an einem urologischen Patientengut zur Frage des Einflusses des Acetyliererstatus und anderer Faktoren bei der Entstehung von urothelialen Tumoren [dissertation]. Homburg/Saar (Germany): Medical Faculty, University of the Saarland, 1994.
23. Statistisches Bundesamt: Klassifizierung der Berufe. Systematisches und alphabetisches Verzeichnis der Berufsbenennungen. Stuttgart: Metzler-Pöschel Verlag 1992.
24. Cascorbi I, Drakoulis N, Brockmöller J, Maurer A, Sperling K, Roots I. Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity. Am J Hum Genet 1995; 57:581-92.
25. Grant DM. Molecular genetics of N-acetyltransferases. Pharmacogenetics 1993;3:45-50.
26. Vatsis KP, Weber WW, Bell DA, Dupret JU, Evans DAP, Grant DM, et al. Nomenclature for N-acetyltransferases. Pharmacogenetics 1995;5:1-17.
27. Röhrkasten R, Raatz P, Kreher RP, Blaszkewicz M. Synthesis of the caffeine metabolite 5-acetylamino-6-formylamino-3- methyluracil (AFMU) and 5-acetylamino-6-amino-3-methyluracil (AAMU) on a preparative scale. Z Naturforsch [B]. In press.
28. Fink K, Adams WS, Pfleiderer W. A new urinary pyrimidine, 5-acetyl-6-amino-3-methyluracil, its isolation, identification and synthesis. J Biol Chem 1964;239:4250-6.
29. Butler MA, Lang NP, Young JF, Caporaso NE, Vineis P, Hayes RB, et al. Determination of CYP1A2 and NAT 2 phenotypes in human populations by analysis of caffeine urinary metabolites. Pharmacogenetics 1992;2:116-27.
30. Grant DM, Tang BK, Kalow W. Variability in caffeine metabolism. Clin Pharmacol Ther 1983;33:591-602.
31. Braz Vieira de Silva Pontes Z, Vincent-Viry M, Gueguen R, Gatteau MM, Siest G. Acetylation phenotypes and biological variation in a French Caucasian population. Eur J Clin Biochem 1993;31:59-67.
32. Vistisen K, Poulsen HE, Loft S. Foreign compound metabolism capacity in man measured from metabolites of dietary caffeine. Carcinogenesis 1992;13:1561-8.
33. Schöps W, Prior V, Golka K, Blaszkewicz M, Cascorbi I Roots I, et al. Untersuchung zur klinischen Relevanz der Acetyliererphänotypisierung bei 196 Urotheltumorpatienten. Urologe [A]. In press.
34. Bolt HM, Jorritsma U, Golka K. Zur Frage der arbeitsmedizinischen Begutachtung von Harnblasentumoren bei Exposition gegen aromatische Amine (BK Nr. 1301). Z Arbeitswiss 1993;47:(19NF),50-6.
35. Hammond SK, Coghlin J, Gann PH, Paul M, Taghizadeh K, Skipper PJ, et al. Relationship between environmental tobacco smoke exposure and carcinogen-hemoglobin adduct levels in non-smokers. JNCI 1993;85:474-7.
36. Luceri F, Moneti G. Bestimmung des Amingehaltes im Zigarettenrauch. HP Peak 1994;1:2-3.
37. Bell DA, Thompson CL, Taylor J, Miller CR, Perera F, Hsieh LL, et al. Genetic monitoring of human polymorphic cancer susceptibility genes by polymerase chain reaction: application to glutathione transferase μ. Environ Health Perspect 1992;98:113-7.
38. Kihara M, Noda K. Lung cancer risk of GSTM1 null genotype is dependent on the extent of tobacco smoke exposure. Carcinogenesis 1994;15:415-8.
39. Bell DA, Taylor JA, Paulson DF, Robertson CN, Mohler JL, Lucier GW. Genetic risk and carcinogen exposure: a common inherited defect of the carcinogen-metabolism gene glutathione S-transferase Ml (GSTM1) that increases susceptibility to bladder cancer. JNCI 1993;85:1159-64.